https://orcid.org/0000-0002-5235-1780
Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kevin Jackson, C. Ellis Wisely, Brian M. Davis, Brian Griffin & Terry Kim. (2020) Real-world opioid prescribing after cataract surgery among patients who received intracameral phenylephrine and ketorolac 1.0%/0.3%. Current Medical Research and Opinion 36:12, pages 2047-2052.
Read now
Read now
Articles from other publishers (5)
Akash Gowda, Wilson Wong Jun Jie, Robert Casson & Weng Onn Chan. (2022) The safety of intracameral phenylephrine – A systematic review. Survey of Ophthalmology 67:5, pages 1540-1546.
Crossref
Crossref
Eric D. Donnenfeld, Daniel Mychajlyszyn, Andrey Mychajlyszyn & Rebecca Stein. (2022) Pain control and reduction of opioid use associated with intracameral phenylephrine1.0%–ketorolac 0.3% administered during cataract surgery. Journal of Cataract and Refractive Surgery 48:7, pages 759-764.
Crossref
Crossref
Akshay J Reddy, Allen Dang, Amy A Dao, Gordon Arakji, Joshua Cherian & Hetal Brahmbhatt. (2021) A Substantive Narrative Review on the Usage of Lidocaine in Cataract Surgery. Cureus.
Crossref
Crossref
Matthew R. Starr, Luv G. Patel, Michael Ammar & Yoshihiro Yonekawa. (2021) Opioids and ophthalmology: review of the current literature. Current Opinion in Ophthalmology 32:3, pages 209-213.
Crossref
Crossref
M. Edward Wilson, Rupal H. Trivedi & David A. Plager. (2020) Safety and efficacy data supporting U.S. FDA approval of intracameral phenylephrine and ketorolac 1.0%/0.3% for pediatric cataract surgery: clinical safety and pupil and pain management. Journal of Cataract and Refractive Surgery 46:6, pages 873-878.
Crossref
Crossref